Home / CANCER BUZZ Podcast

CANCER BUZZ Podcast

CANCER BUZZ, the ACCC podcast, has a fresh new look!

The refresh of the CANCER BUZZ logo reflects our commitment to hosting timely, relevant discussions with our multidisciplinary membership. From the front desk to the C-suite, from clinical research to cancer survivorship, and everywhere in between, CANCER BUZZ is the place where oncology leaders and disruptors connect on the most pressing questions and innovations shaping cancer care today.

Listen to the CANCER BUZZ podcast on Apple Podcasts, Spotify, Amazon Music, or wherever you get your podcasts. You can now listen with your smart home device. For instructions on how to listen with Alexa, click here, or just tell Alexa to "Play CANCER BUZZ." For Google Home instructions, click here.

Filter By Topic

Clear filter

Filter By Podcast Format

 
 
 
 
 
    Displaying results 1 - 20 of 26
  • 1
  • 2
  • »
Claudin 18.2 is a novel biomarker for advanced gastric and gastroesophageal junction cancer. Patients who test positive for claudin 18.2 may be candidates for the monoclonal antibody, zolbetuximab, which directly targets this biomarker. In this episode, CANCER BUZZ speaks with Manish A. Shah, MD, FASCO, director of the Gastrointestinal Oncology Program at Weill Cornell Medicine, about how claudin …
Fibroblast growth factor receptor 2 isoform IIIb (FGFR2b) is an emerging biomarker present in about 38% of patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. In this episode, CANCER BUZZ speaks with Nataliya Uboha, MD, PhD, a medical oncologist at University of Wisconsin Health, about current recommendations for biomarker testing in this population, emerging biomarkers …
Effective management of adverse events and addressing barriers to care are critical to optimizing outcomes and maintaining quality of life for patients receiving CDK4/6 inhibitors. In this episode, CANCER BUZZ speaks with Julia Lea Ziegengeist, PharmD, BCOP, clinical pharmacist coordinator in solid tumor oncology at Atrium Health Levine Cancer Institute about proactive, team-based strategies to …
Anticipating and managing CDK4/6 inhibitor toxicities in HR+ HER2- breast cancer is essential to improving patient quality of life and optimizing clinical outcomes. In this episode, CANCER BUZZ speaks with Diana Van Ostran, PharmD, BCOP, clinical pharmacy specialist – breast clinic at Miami Cancer Institute, Baptist Health South Florida, about strategies to monitor and manage treatment-related …
Genetic factors play a critical role in prostate cancer treatment planning, with both germline and somatic mutations guiding therapeutic decisions. The Association of Cancer Care Centers (ACCC) remains committed to improving prostate cancer care and has developed the Metastatic Prostate Cancer Handbook: A Guide to Optimizing Outcomes with Germline and Somatic Testing. In this episode, CANCER BUZZ speaks …
Bispecific antibodies (BsAbs) have the potential to transform cancer treatment and are being actively integrated into community oncology practices. To support oncology practices as they introduce BsAbs into their treatment protocols, the Association of Cancer Care Centers (ACCC) has developed a comprehensive blueprint for this process. This resource highlights key strategies, best practices, and considerations …
In this episode, CANCER BUZZ speaks with Jean Louise Koff, MD, MSc, associate professor of hematology and medical oncology at Winship Cancer Institute of Emory University, to discuss the impact of bispecific antibodies on cancer treatment outcomes, and the challenges and opportunities of integrating this innovative approach into community oncology practices.
In this episode, CANCER BUZZ speaks with Jeff Sharman, MD, medical director of hematology research, US Oncology, and director of research, Willamette Valley Cancer Institute, about the role of biomarker testing in guiding treatment decisions and how evidence-based management of treatment-related adverse events can serve this patient population.
Hear about the evolution of artificial intelligence in precision oncology and the clinical impact of tech-based solutions.
CANCER BUZZ previews the sessions, people and topics of this week’s ACCC 40th National Oncology Conference. We interview Kathy Oubre, MS, CEO of the Pontchartrain Canter Center, about helping patients overcome access barriers to biomarker testing.
It is important for the cancer team to be able to recognize what a small cell might look like — such as central location of the tumor, bulky adenopathy generally.
To standardize comprehensive biomarker testing in patients with NSCLC, Oncology Hematology Care, Inc., developed and implemented a 1-year quality improvement (QI) project that included custom data reports and monitoring dashboards to ensure practice-wide adoption and sustainability across multiple clinic sites.
In this episode, hear about the fully remote TRACK (Target Rare Cancer Knowledge) clinical trial and its unique approach to providing access to biomarker testing for patients in community care settings by leveraging technology.
CANCER BUZZ speaks with Susan Spinosa, president and patient founder of NTRKers, an organization created to support patients with NTRK fusion-positive cancer, about her care journey and the importance of testing for NTRK gene fusions.
Stephen Quake, PhD, spoke to CANCER BUZZ about the application of liquid biopsies across multiple cancer stages and their potential to improve patient outcomes, minimize financial toxicity, and create health equity through greater testing access and lower cost.
Precision medicine is increasingly critical to selecting the right treatment for patients with cancer, but pathology reporting can be lengthy, complex, and confusing—especially in this fast-paced molecular era. Hear one provider’s suggestions for simplifying and standardizing pathology reports so patients can be better informed, understand their prognosis, and own the progress of their therapies.
Biomarker testing is crucial to precision medicine, but barriers still exist. Learn from two healthcare advocates about recent policy changes designed to ensure better access to biomarker testing.
Hear from two authors of an ACCC/LUNGevity Foundation study that identified key areas of clinician need related to biomarker testing in NSCLC.
Genetic counselors—as members of the cancer care team—can help patients better understand their cancer diagnosis, make informed treatment decisions, and navigate the financial costs of testing.
Learn about the current clinical applications of liquid biopsies, associated reimbursement issues, and what you can do to implement these tests at your program.
    Displaying results 1 - 20 of 26
  • 1
  • 2
  • »
The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Community Cancer Centers.